Quick Answer
Transcode Therapeutics, Inc. reported Stockholders Equity of -$2.02 million for the year ending 2024.
- Transcode Therapeutics, Inc. showed a decrease of -223.0% in Stockholders Equity from 2023 to 2024.
- This data is from Transcode Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2019 to 2024 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$1.15 million | Q2 2020: -$1.28 million | Q3 2020: -$2.62 million | Q1 2021: -$7.85 million | Q2 2021: -$5.04 million | Q3 2021: $23.16 million | Q1 2022: $17.00 million | Q2 2022: $12.43 million | Q3 2022: $8.24 million | Q1 2023: -$236.8 thousand | Q2 2023: $2.09 million | Q3 2023: $4.44 million | Q4 2023: $1.64 million | Q1 2024: $4.58 million | Q2 2024: $1.32 million | Q3 2024: $1.65 million | Q4 2024: -$2.02 million | Q1 2025: $10.29 million | Q2 2025: $6.15 million | Q3 2025: $1.43 million.
- Over the full 6 years of available data (2019 to 2024), Transcode Therapeutics, Inc.'s Stockholders Equity has declined by 81.9%.
- Historical annual values: Fiscal year 2024: -$2.02 million | Fiscal year 2023: $1.64 million | Fiscal year 2022: $3.24 million | Fiscal year 2021: $20.40 million | Fiscal year 2020: -$3.41 million | Fiscal year 2019: -$1.11 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: